* Emerging therapies (Pipeline assessment and
key clinical trials profile)
* Epidemiology (Incidence, prevalence,
mortality and survival)
* Market share and patient share uptake
* KOL’s perspective on current treatment &
unmet needs
* Market and product event analysis
* Market forecast 2018 - 2030 (11 years of
future market projections)
Report Summary
Thelansis “Acute
Respiratory Distress Syndrome (ARDS) - Market outlook, Epidemiology,
Market Forecast and Competitive Landscape - 2018 To 2030 ” this report provides a comprehensive study of
the disease area landscape and changing market dynamics with respect to the current & future market
events for the 8 MM countries (USA, EU5, Japan & China).
Report Overview
The report provides a comprehensive view of disease
events, types, severity level, risk factors, eligible patient pool for
mechanical ventilation, identified and emerging biomarkers, progression,
manifestations, symptoms, risk factors, pathogenesis, genetic basis and
treatment guidelines at country level.
* Comprehensive insight on patient segmentation based
on severity (mild, moderate and severe), by risk factors
(Pneumonia, Sepsis, Trauma, Aspiration, Pancreatitis, others) and
Non-risk factor associated, Patients eligible for mechanical ventilation
(Noninvasive ventilation, and Invasive ventilation) has been provided into
the epidemiology (Incidence and Prevalence) section of the Acute Respiratory
Distress Syndrome (ARDS) and its treatment in the 8 MM countries, covering the
United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.
* Drug utilization and analysis on the current
clinical practice (Neuromuscular Blockade, Inhaled vasodilators,
Corticosteroids, Recruitment maneuvers, Prone Positioning, ECMO, HFOV,
Esophageal pressure catheter, Tracheostomy and others), KOL perspective on
upcoming therapies, estimated TPP for pipeline assets, clinical characteristics
upcoming therapies and future treatment paradigm.
* Market aggregation on newly diagnosed patient pool,
Thelansis estimation on persistence, compliance, adherence and a historic view
of changing market dynamics and product-level patient flow of ARDS in
the 8 MM Countries for the period 2018 - 2030.
* A comprehensive
record of both the present and rising disease burden with respect to the
treatments for ARDS are provided, along with impact of the new
treatments and the probable patent expiry considering the current market
dynamics. A detailed review of 8MM current and forecasted market
including the drug outreach at different country level based on their order of
entry.
Disease overview:
Acute lung
injury (ALI) is a common condition characterized by acute severe hypoxia that
is not due to left atrial hypertension. The term ALI encompasses a continuum of
clinical and radiographic changes that affect the lungs with the acute
respiratory distress syndrome (ARDS) representing the more severe end of
this continuum. Despite of advances in understanding of the pathophysiology and
management, it is still associated with a high mortality.
Epidemiology
* The total incident
population of ARDS in the 8MM ranges from 1,204,916 in 2018 to 1,482,491 by
2030, growing at a CAGR of x.x% during the study period. Among the European 5
countries, Germany had the highest incident population of ARDS with xxx,xxx
cases, followed by Italy, which had the incident population of xxxxx in 2018.
* According to
Thelansis, the incident population of Acute Kidney Injury will significantly
increase at a CAGR of X% during the period 2018-2030 in 8 MM markets.
Market Scenario:
Treatment of ARDS is supportive, including mechanical ventilation, prevention of stress ulcers and venous thromboembolism, and nutritional support. Good supportive care, as for all ICU patients, should include nutritional support with an aim for early enteral feeding, good glycaemic control, and deep venous thrombosis and stress ulceration prophylaxis.
Competitive Landscape
In terms of
pharmacologic therapies, several drug candidates are in Phase III, II and I
stages of development by various companies. Key assets among these are
Traumakine romPharmaceuticals - 11006 from Pharmaceuticals, from Bioscience,
Ulinastatin fromBio-Pharma, MultiStem from Athersys, AP301 from Apeptico
Forschung und Entwicklung GmbH.
KOL perspective:
* “…..No approved therapies, identification of novel
renal biomarkers for clinical use, and progress in understanding the underlying
pathophysiology, there are remains a major unmet medical need …..…quality of
life…...” (Department of Respiratory and Critical Care Medicine, Michigan
University , USA).
Market Forecast:
Thelansis’ research team expects the Acute Respiratory Distress
Syndrome (ARDS) market potential for 2030 at $X.XXB in 8MM countries. Out of
this market, 68.5% sales are expected to be contributed from the US market
whereas XX.X% is expected to come from EU-5. Japan and China are expected to
contribute XX.X% and X.X% respectively.
Contact Us
About Thelansis:
- As the name depicts Thelansis is specialized in “Therapy Area Landscape
Analy-sis” along with market
intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies
to successfully prepare, launch, and commercialize their products. Our
Syndicated research reports
include Market Insight,
Pipeline Insight, Product
Insight, Specialized Reports, Indication Outlook and Market
Access Reports.
Visit us at http://www.thelansis.com/
Delivery office
B-1030, C Wing
Vrindavan tech village
Marathahalli
Outer ring road, Bangalore-
560037
Contact no. India : +91(124)
404-1731
Sales office
183-Asylum Street Hartfort,
CT-06103, USA
Telephone:
USA +1 (267) 244-6955,
Email: clientsupport@thelansis.com
No comments:
Post a Comment